Ahmed Farrag
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ahmed Farrag has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- Anica Ilic
Faculty of Health Sciences and Medicine University of Lucerne Lucerne Switzerland
2 shared publications - Cristina Priboi
Veterinary Public Health Institute, University of Bern 1 , Bern, Switzerland
2 shared publications Elena Lemmel
Pediatric Hematology and Oncology Unit, Department of Pediatrics, University Hospital Center Lausanne, Lausanne, Switzerland
2 shared publications- Freimut Schilling
Children´s Hospital, Olgahospital, Stuttgart, Germany
2 shared publications - Gisela Michel
Faculty of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland
2 shared publications - Hans Christiansen
Klinik für Strahlentherapie und Spezielle Onkologie, Medizinische Hochschule Hannover, Hannover, Deutschland
2 shared publications
Latest Publications
- Open Access
- 11 September 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (9) , 553
Quality of Life in Ukrainian Children and Adolescents with Cancer Relocated to Switzerland During the Russian–Ukrainian War: An Exploratory Multicenter Study
The war in Ukraine, beginning in February 2022, disrupted continuous medical care for Ukrainian childhood and adolescent cancer patients (UCC), many of whom were relocated to pediatric cancer centers worldwide, including Switzerland. In this Brief Report, we describe their health-related quality of life (HRQoL) after arrival. In a multicenter, cross-sectional survey across five Swiss pediatric oncology centers, we included patients ≤18 years at diagnosis who arrived after 24 February 2022 and were undergoing active treatment. HRQoL was assessed by the PedsQL™ 4.0 Generic Core Scales (self- and parent-reports). Fourteen of 23 eligible families (61%) participated. HRQoL declined with age, particularly in physical functioning, while psychosocial functioning remained relatively stable but lower among adolescents; parent scores closely matched self-reports. Scores were referenced against a published cohort of healthy Ukrainian children and previously reported pediatric cancer populations. Given the small sample and lack of a matched control group, the findings cannot separate the effects of displacement, cancer, and treatment and are hypothesis-generating. They suggest a potential role for age-tailored supportive care in displaced children with cancer and call for larger, controlled studies.
- 11 September 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (9) , 553
Open AccessQuality of Life in Ukrainian Children and Adolescents with Cancer Relocated to Switzerland During the Russian–Ukrainian War: An Exploratory Multicenter Study
The war in Ukraine, beginning in February 2022, disrupted continuous medical care for Ukrainian childhood and adolescent cancer patients (UCC), many of whom were relocated to pediatric cancer centers worldwide, including Switzerland. In this Brief Report, we describe their health-related quality of life (HRQoL) after arrival. In a multicenter, cross-sectional survey across five Swiss pediatric oncology centers, we included patients ≤18 years at diagnosis who arrived after 24 February 2022 and were undergoing active treatment. HRQoL was assessed by the PedsQL™ 4.0 Generic Core Scales (self- and parent-reports). Fourteen of 23 eligible families (61%) participated. HRQoL declined with age, particularly in physical functioning, while psychosocial functioning remained relatively stable but lower among adolescents; parent scores closely matched self-reports. Scores were referenced against a published cohort of healthy Ukrainian children and previously reported pediatric cancer populations. Given the small sample and lack of a matched control group, the findings cannot separate the effects of displacement, cancer, and treatment and are hypothesis-generating. They suggest a potential role for age-tailored supportive care in displaced children with cancer and call for larger, controlled studies.
- Open Access
Evaluating the Prognostic Relevance of Pre-Treatment Epstein–Barr Virus Levels in Non-Endemic Pediatric Nasopharyngeal Carcinoma
Background/Objectives: Pediatric nasopharyngeal carcinoma (NPC) is a very rare childhood cancer strongly associated with Epstein–Barr virus (EBV) infection. We investigated the prognostic value of EBV DNA on staging and outcome in pediatric NPC from two large study centers, the Children’s Oncology Group (COG) in North America and the German Society of Pediatric Oncology and Hematology (GPOH) in Europe. Methods: Samples collected from NPC patients treated on the COG study ARAR0331 between 2006 and 2012 and the GPOH NPC protocol between 2003 and 2021 were retrospectively analyzed for the level of available plasma (P-EBV) or whole-blood EBV DNA (WB-EBV), both pre-treatment and post-induction chemotherapy. Patients were dichotomized into high and low groups based on the median pre-treatment EBV value. Results: Pre-treatment EBV DNA levels from 102 patients (50 and 23 P-EBV DNA from the COG and GPOH, respectively, and 29 WB-EBV from GPOH) and post-induction EBV DNA levels from 61 patients (31 and 12 P-EBV DNA from the COG and GPOH, respectively, and 18 WB-EBV DNA from GPOH) were evaluated. Patient characteristics, including age and disease stage, were not associated with high and low P-EBV values in any cohort. Disease stage correlated with high EBV levels in the WB-EBV GPOH cohort (p = 0.014). Pre-treatment P-EBV and WB-EBV levels showed no significant association with 5-year event-free survival (EFS: COG p = 0.65, GPOH P-EBV: p = 0.08, GPOH WB-EBV: p = 0.75) or 5-year overall survival (OS: COG p = 0.90, GPOH P-EBV p = 0.17, GPOH WB-EBV p = 0.19). Conclusions: Our study could not establish a significant correlation between outcome and pre-treatment EBV DNA in pediatric NPC patients from non-endemic areas.
Open AccessEvaluating the Prognostic Relevance of Pre-Treatment Epstein–Barr Virus Levels in Non-Endemic Pediatric Nasopharyngeal Carcinoma
Background/Objectives: Pediatric nasopharyngeal carcinoma (NPC) is a very rare childhood cancer strongly associated with Epstein–Barr virus (EBV) infection. We investigated the prognostic value of EBV DNA on staging and outcome in pediatric NPC from two large study centers, the Children’s Oncology Group (COG) in North America and the German Society of Pediatric Oncology and Hematology (GPOH) in Europe. Methods: Samples collected from NPC patients treated on the COG study ARAR0331 between 2006 and 2012 and the GPOH NPC protocol between 2003 and 2021 were retrospectively analyzed for the level of available plasma (P-EBV) or whole-blood EBV DNA (WB-EBV), both pre-treatment and post-induction chemotherapy. Patients were dichotomized into high and low groups based on the median pre-treatment EBV value. Results: Pre-treatment EBV DNA levels from 102 patients (50 and 23 P-EBV DNA from the COG and GPOH, respectively, and 29 WB-EBV from GPOH) and post-induction EBV DNA levels from 61 patients (31 and 12 P-EBV DNA from the COG and GPOH, respectively, and 18 WB-EBV DNA from GPOH) were evaluated. Patient characteristics, including age and disease stage, were not associated with high and low P-EBV values in any cohort. Disease stage correlated with high EBV levels in the WB-EBV GPOH cohort (p = 0.014). Pre-treatment P-EBV and WB-EBV levels showed no significant association with 5-year event-free survival (EFS: COG p = 0.65, GPOH P-EBV: p = 0.08, GPOH WB-EBV: p = 0.75) or 5-year overall survival (OS: COG p = 0.90, GPOH P-EBV p = 0.17, GPOH WB-EBV p = 0.19). Conclusions: Our study could not establish a significant correlation between outcome and pre-treatment EBV DNA in pediatric NPC patients from non-endemic areas.
- Open Access
- 12 August 2026
- Published by Elsevier in Patient Education and Counseling
- Vol. 152, 109811
“It has never been exactly what I was looking for”: information needs of grandparents after a grandchild’s cancer diagnosis – results from a multicenter mixed-methods study (GROKids Project)
- 12 August 2026
- Published by Elsevier in Patient Education and Counseling
- Vol. 152, 109811
Open Access“It has never been exactly what I was looking for”: information needs of grandparents after a grandchild’s cancer diagnosis – results from a multicenter mixed-methods study (GROKids Project)
- Open Access
- 7 April 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (4) , e71774
Longitudinal Analysis of Psychological Distress in Grandparents of Children With Cancer: Results From a Multicenter Cohort Study in Switzerland ( GROKids Project)
Objectives: This exploratory study assessed psychological distress of grandparents of children recently diagnosed with cancer within 2 years post‐diagnosis. We examined changes over time, identified associated factors, and compared distress levels with a comparison group (grandparents of survivors). Methods: Grandparents were recruited via parents of children recently diagnosed with cancer (within 3 months). Survivors (3–10 years post‐diagnosis) were asked to provide contact information of their grandparents (comparison group). Grandparents completed surveys at 3 (T1), 6 (T2), 12 (T3), and 24 months (T4) post‐diagnosis. The comparison group completed a questionnaire once. Psychological distress was assessed using the Brief Symptom Inventory‐18, with three subscales (depression, anxiety, somatization), and an overall score (Global Severity Index; GSI). Scores were T‐standardized. We used linear mixed models to compare distress across time points and linear regressions for between‐group differences (grandparents versus comparison group). Results: Forty‐one grandparents (mean age = 68 years, 59% female) of 20 patients participated. In the comparison group 133 grandparents (mean age = 72 years, 60% female) of 66 survivors (mean years post‐diagnosis = 6.7, SD = 2.3) participated. GSI scores were all below normative values. Increases in GSI were observed from T1 to T2 (24%) and T3 to T4 (26%). Greater distance from the child's hospital was associated with lower GSI ( β : −13.27, p = 0.033) and anxiety scores ( β : −5.50, p = 0.017). Grandfathers reported higher levels of somatization than grandmothers ( β : 4.00, p = 0.071). Older age was associated with lower anxiety ( β : −9.86, p = 0.042). Conclusion: Although most grandparents reported psychological distress within normative ranges, distress levels increased in some. Targeted interventions might help support grandparents of children with cancer.
- 7 April 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (4) , e71774
Open AccessLongitudinal Analysis of Psychological Distress in Grandparents of Children With Cancer: Results From a Multicenter Cohort Study in Switzerland ( GROKids Project)
Objectives: This exploratory study assessed psychological distress of grandparents of children recently diagnosed with cancer within 2 years post‐diagnosis. We examined changes over time, identified associated factors, and compared distress levels with a comparison group (grandparents of survivors). Methods: Grandparents were recruited via parents of children recently diagnosed with cancer (within 3 months). Survivors (3–10 years post‐diagnosis) were asked to provide contact information of their grandparents (comparison group). Grandparents completed surveys at 3 (T1), 6 (T2), 12 (T3), and 24 months (T4) post‐diagnosis. The comparison group completed a questionnaire once. Psychological distress was assessed using the Brief Symptom Inventory‐18, with three subscales (depression, anxiety, somatization), and an overall score (Global Severity Index; GSI). Scores were T‐standardized. We used linear mixed models to compare distress across time points and linear regressions for between‐group differences (grandparents versus comparison group). Results: Forty‐one grandparents (mean age = 68 years, 59% female) of 20 patients participated. In the comparison group 133 grandparents (mean age = 72 years, 60% female) of 66 survivors (mean years post‐diagnosis = 6.7, SD = 2.3) participated. GSI scores were all below normative values. Increases in GSI were observed from T1 to T2 (24%) and T3 to T4 (26%). Greater distance from the child's hospital was associated with lower GSI ( β : −13.27, p = 0.033) and anxiety scores ( β : −5.50, p = 0.017). Grandfathers reported higher levels of somatization than grandmothers ( β : 4.00, p = 0.071). Older age was associated with lower anxiety ( β : −9.86, p = 0.042). Conclusion: Although most grandparents reported psychological distress within normative ranges, distress levels increased in some. Targeted interventions might help support grandparents of children with cancer.
- 3 October 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (12) , e32096
Two Surveys, 16 Years Apart: Comparing Traditional and Complementary Medicine Use by Children With Cancer in Jordan
Background: Traditional and complementary medicine (T&CM) is commonly used by children with cancer alongside conventional treatments. However, data on its use in Jordan remain limited. This study aimed to assess the current prevalence, types, motivations, and disclosure rates of T&CM use in Jordan, and to compare these findings with those from the original 2008 study conducted in the same setting. Methods: A cross‐sectional study was conducted in the pediatric oncology department at King Hussein Cancer Center between November 2023 and May 2024. A brief proxy‐report T&CM questionnaire with evidence of validity and reliability was used. Results: A total of 85 patients participated (response rate = 85%). Overall, 29.4% reported T&CM use, primarily for perceived safety (52%), managing cancer‐related symptoms (44%), and potential therapeutic benefit (40%). Nutritional (68%) and psychological (24%) approaches were the most used modalities. Disclosure of T&CM use to healthcare providers was reported by 75% of users. Reasons for non‐use included a lack of recommendation by healthcare providers and limited awareness. A statistically significant association was found between T&CM use and current therapy stage, with higher use among patients in active treatment. No other demographic or clinical variables were significantly associated with T&CM use. Conclusion: Compared to earlier findings, this study shows a lower prevalence of T&CM use and a higher disclosure rate, suggesting improved communication and awareness. Parents used T&CM to complement conventional care rather than as an alternative. These findings underscore the importance of integrating discussions about T&CM into pediatric oncology care to support safe and informed use.
- 3 October 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (12) , e32096
Two Surveys, 16 Years Apart: Comparing Traditional and Complementary Medicine Use by Children With Cancer in Jordan
Background: Traditional and complementary medicine (T&CM) is commonly used by children with cancer alongside conventional treatments. However, data on its use in Jordan remain limited. This study aimed to assess the current prevalence, types, motivations, and disclosure rates of T&CM use in Jordan, and to compare these findings with those from the original 2008 study conducted in the same setting. Methods: A cross‐sectional study was conducted in the pediatric oncology department at King Hussein Cancer Center between November 2023 and May 2024. A brief proxy‐report T&CM questionnaire with evidence of validity and reliability was used. Results: A total of 85 patients participated (response rate = 85%). Overall, 29.4% reported T&CM use, primarily for perceived safety (52%), managing cancer‐related symptoms (44%), and potential therapeutic benefit (40%). Nutritional (68%) and psychological (24%) approaches were the most used modalities. Disclosure of T&CM use to healthcare providers was reported by 75% of users. Reasons for non‐use included a lack of recommendation by healthcare providers and limited awareness. A statistically significant association was found between T&CM use and current therapy stage, with higher use among patients in active treatment. No other demographic or clinical variables were significantly associated with T&CM use. Conclusion: Compared to earlier findings, this study shows a lower prevalence of T&CM use and a higher disclosure rate, suggesting improved communication and awareness. Parents used T&CM to complement conventional care rather than as an alternative. These findings underscore the importance of integrating discussions about T&CM into pediatric oncology care to support safe and informed use.
- Open Access
- 28 October 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (10) , e0312663
Pediatric cancer mortality: Analyzing early deaths and fatalities in a resource-limited tertiary care context
Introduction: Children with suspected cancer may succumb to their bad condition shortly after admission, even before a definitive diagnosis can be reached. We aimed to address the issue of delayed presentation and early deaths among children suspected of having cancer. We analyzed also the types and causes of mortalities across different tumor types. Materials and methods: A retrospective review of reports from newly admitted patients between 2006 and 2010 at the pediatric oncology department of the South Egypt Cancer Institute (SECI) was done. Parameters included age, gender, diagnosis, symptoms, the interval between initial symptoms and the first visit to SECI, the duration from admission to death, and the cause of death. Results: Among the 502 patients with confirmed malignancies, 238 (47.4%) succumbed. Causes of death were predominantly treatment-related mortalities (TRM) (66%). Mortalities within hematological malignancies were mainly TRM (81%), whereas solid tumors were primarily disease-related (70%), p <0.0001. The leading causes of TRM was infection (60%). About 5% of patients experienced early death within 48 hours after presenting to SECI. The mean duration from initial symptoms to the first SECI visit was 67 days, and the period from admission to death averaged 27 hours. Common initial symptoms included abdominal swelling (29.6%), or fever (26%). The leading causes of death were respiratory failure (29.6%), tumor lysis syndrome (22%), or septicemia (22%). Conclusions: Delayed presentation leading to early deaths poses a significant obstacle to the successful treatment of childhood cancers. Early diagnosis and improved supportive care are essential to enhancing the overall survival, particularly in patients with hematologigical malignancies.
- 28 October 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (10) , e0312663
Open AccessPediatric cancer mortality: Analyzing early deaths and fatalities in a resource-limited tertiary care context
Introduction: Children with suspected cancer may succumb to their bad condition shortly after admission, even before a definitive diagnosis can be reached. We aimed to address the issue of delayed presentation and early deaths among children suspected of having cancer. We analyzed also the types and causes of mortalities across different tumor types. Materials and methods: A retrospective review of reports from newly admitted patients between 2006 and 2010 at the pediatric oncology department of the South Egypt Cancer Institute (SECI) was done. Parameters included age, gender, diagnosis, symptoms, the interval between initial symptoms and the first visit to SECI, the duration from admission to death, and the cause of death. Results: Among the 502 patients with confirmed malignancies, 238 (47.4%) succumbed. Causes of death were predominantly treatment-related mortalities (TRM) (66%). Mortalities within hematological malignancies were mainly TRM (81%), whereas solid tumors were primarily disease-related (70%), p <0.0001. The leading causes of TRM was infection (60%). About 5% of patients experienced early death within 48 hours after presenting to SECI. The mean duration from initial symptoms to the first SECI visit was 67 days, and the period from admission to death averaged 27 hours. Common initial symptoms included abdominal swelling (29.6%), or fever (26%). The leading causes of death were respiratory failure (29.6%), tumor lysis syndrome (22%), or septicemia (22%). Conclusions: Delayed presentation leading to early deaths poses a significant obstacle to the successful treatment of childhood cancers. Early diagnosis and improved supportive care are essential to enhancing the overall survival, particularly in patients with hematologigical malignancies.
- 17 September 2024
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (12) , e31326
Family strategies for managing childhood cancer: Using traditional and complementary medicine in Southern Egypt
Background and purpose: The use of traditional and complementary medicine (T&CM) is common in children with cancer globally. We aimed to assess the prevalence, types, reasons, perceived effectiveness, and disclosure rate of T&CM use among children with cancer in Southern Egypt. We also investigated whether T&CM use contributed to delays in initial presentation and treatment. Materials and methods: A cross‐sectional design was utilized. Data were collected via an interviewer‐administered questionnaire. Eligible children and their caregivers at the South Egypt Cancer Institute were invited to participate. Results: Eighty‐six children completed the study (response rate = 86%). T&CM use was reported by 52 (60.5%) patients, with six (11.5%) experienced delayed presentation. The reasons for T&CM use were complementary for 37 (71%) and alternative for 15 (29%) of the participants. The types of T&CM used included herbal (63%), nutritional (33%), witchcraft (29%), and religious (19%) therapies. Approximately 48% of users employed multiple T&CM types. Family members recommended T&CM for 60% of the users. Most patients (65%) perceived T&CM as effective, with 71% initiating its use during the early phases of treatment. Almost all participants (98%) reported that healthcare providers did not inquire about T&CM use. T&CM usage was more prevalent among wealthier families ( p = .023). There was no significant relationship between T&CM use and patient gender, diagnosis, residence, or paternal educational level. Conclusions: The significant utilization of T&CM among children with cancer highlights the need for healthcare providers to engage in open and early discussions with families regarding T&CM use.
- 17 September 2024
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (12) , e31326
Family strategies for managing childhood cancer: Using traditional and complementary medicine in Southern Egypt
Background and purpose: The use of traditional and complementary medicine (T&CM) is common in children with cancer globally. We aimed to assess the prevalence, types, reasons, perceived effectiveness, and disclosure rate of T&CM use among children with cancer in Southern Egypt. We also investigated whether T&CM use contributed to delays in initial presentation and treatment. Materials and methods: A cross‐sectional design was utilized. Data were collected via an interviewer‐administered questionnaire. Eligible children and their caregivers at the South Egypt Cancer Institute were invited to participate. Results: Eighty‐six children completed the study (response rate = 86%). T&CM use was reported by 52 (60.5%) patients, with six (11.5%) experienced delayed presentation. The reasons for T&CM use were complementary for 37 (71%) and alternative for 15 (29%) of the participants. The types of T&CM used included herbal (63%), nutritional (33%), witchcraft (29%), and religious (19%) therapies. Approximately 48% of users employed multiple T&CM types. Family members recommended T&CM for 60% of the users. Most patients (65%) perceived T&CM as effective, with 71% initiating its use during the early phases of treatment. Almost all participants (98%) reported that healthcare providers did not inquire about T&CM use. T&CM usage was more prevalent among wealthier families ( p = .023). There was no significant relationship between T&CM use and patient gender, diagnosis, residence, or paternal educational level. Conclusions: The significant utilization of T&CM among children with cancer highlights the need for healthcare providers to engage in open and early discussions with families regarding T&CM use.
- 23 September 2023
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 41 (1) , 41-53
Noncompliance of pediatric cancer patients with chemotherapy: A single-center experience in a lower-middle income country
Noncompliance with therapy is a big obstacle to successful therapy. We aimed to evaluate the prevalence and risk factors affecting the compliance of pediatric cancer patients with therapy in a tertiary care center far away from the capital in a lower-middle income country (LMIC). A retrospective cohort study of reports of all pediatric cancer patients who were diagnosed and started treatment between 2006 and 2010 at South Egypt Cancer Institute (SECI) was done. The following data were collected: Age, sex, diagnosis, compliance with therapy, and data on potential risk factors that might affect compliance, including time duration of travel from the patient's home to SECI, time lag between the first symptom until the first visit to SECI and until the start of treatment, results of reevaluation after the initial course of therapy, and therapy-related severe adverse events. Noncompliance with therapy was defined as when patients missed their determined therapy appointment for one week or more or abandoned therapy. This study included 510 patients. Eighty-three (16.3%) were non-compliant, as forty patients missed their therapy appointment (7.8%), and 43 abandoned further therapy (8.4%). Noncompliance was found to be more prevalent among patients with solid tumors. Non-compliant patients suffered a significantly higher relapse rate (47.7% vs. 11.2% in compliant patients, p < .001). Unfortunately, 75% of the abandoned patients who returned for further therapy suffered a relapse. Noncompliance with treatment is still a big problem facing cancer management in LMICs.
- 23 September 2023
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 41 (1) , 41-53
Noncompliance of pediatric cancer patients with chemotherapy: A single-center experience in a lower-middle income country
Noncompliance with therapy is a big obstacle to successful therapy. We aimed to evaluate the prevalence and risk factors affecting the compliance of pediatric cancer patients with therapy in a tertiary care center far away from the capital in a lower-middle income country (LMIC). A retrospective cohort study of reports of all pediatric cancer patients who were diagnosed and started treatment between 2006 and 2010 at South Egypt Cancer Institute (SECI) was done. The following data were collected: Age, sex, diagnosis, compliance with therapy, and data on potential risk factors that might affect compliance, including time duration of travel from the patient's home to SECI, time lag between the first symptom until the first visit to SECI and until the start of treatment, results of reevaluation after the initial course of therapy, and therapy-related severe adverse events. Noncompliance with therapy was defined as when patients missed their determined therapy appointment for one week or more or abandoned therapy. This study included 510 patients. Eighty-three (16.3%) were non-compliant, as forty patients missed their therapy appointment (7.8%), and 43 abandoned further therapy (8.4%). Noncompliance was found to be more prevalent among patients with solid tumors. Non-compliant patients suffered a significantly higher relapse rate (47.7% vs. 11.2% in compliant patients, p < .001). Unfortunately, 75% of the abandoned patients who returned for further therapy suffered a relapse. Noncompliance with treatment is still a big problem facing cancer management in LMICs.
- Open Access
- 5 September 2023
- Published by Springer Nature in BMC Pediatrics
- Vol. 23 (1) , 1-12
Comparing presentations and outcomes of children with cancer: a study between a lower-middle-income country and a high-income country
Background: Substantial progress has been achieved in managing childhood cancers in many high-income countries (HICs). In contrast, survival rates in lower-middle-income countries (LMICs) are less favorable. Here, we aimed to compare outcomes and associated factors between two large institutions; Egypt (LMIC) and Germany (HIC). Methods: A retrospective review was conducted on newly diagnosed children with cancer between 2006 and 2010 in the departments of pediatric oncology at the South Egypt Cancer Institute (SECI) (n = 502) and the University Hospital of Cologne-Uniklinik Köln (UKK) (n = 238). Characteristics including age, sex, diagnosis, travel time from home to the cancer center, the time interval from initial symptoms to the start of treatment, treatment-related complications, compliance, and outcome were analyzed. A Cox proportional hazards regression model was applied to investigate the influence of risk factors. Results: The most common diagnoses in SECI were leukemia (48.8%), lymphomas (24.1%), brain tumors (1%), and other solid tumors (24.7%), compared to 22.3%, 19.3%, 28.6%, and 26.5% in UKK, respectively. Patients from SECI were younger (5.2 vs. 9.0 years, P < 0.001), needed longer travel time to reach the treatment center (1.44 ± 0.07 vs. 0.53 ± 0.03 h, P < 0.001), received therapy earlier (7.53 ± 0.59 vs. 12.09 ± 1.01 days, P = 0.034), showed less compliance (85.1% vs. 97.1%, P < 0.001), and relapsed earlier (7 vs. 12 months, P = 0.008). Deaths in SECI were more frequent (47.4% vs. 18.1%) and caused mainly by infection (60% in SECI, 7% in UKK), while in UKK, they were primarily disease-related (79% in UKK, 27.7% in SECI). Differences in overall and event-free survival were observed for leukemias but not for non-Hodgkin lymphoma. Conclusions: Outcome differences were associated with different causes of death and other less prominent factors.
- 5 September 2023
- Published by Springer Nature in BMC Pediatrics
- Vol. 23 (1) , 1-12
Open AccessComparing presentations and outcomes of children with cancer: a study between a lower-middle-income country and a high-income country
Background: Substantial progress has been achieved in managing childhood cancers in many high-income countries (HICs). In contrast, survival rates in lower-middle-income countries (LMICs) are less favorable. Here, we aimed to compare outcomes and associated factors between two large institutions; Egypt (LMIC) and Germany (HIC). Methods: A retrospective review was conducted on newly diagnosed children with cancer between 2006 and 2010 in the departments of pediatric oncology at the South Egypt Cancer Institute (SECI) (n = 502) and the University Hospital of Cologne-Uniklinik Köln (UKK) (n = 238). Characteristics including age, sex, diagnosis, travel time from home to the cancer center, the time interval from initial symptoms to the start of treatment, treatment-related complications, compliance, and outcome were analyzed. A Cox proportional hazards regression model was applied to investigate the influence of risk factors. Results: The most common diagnoses in SECI were leukemia (48.8%), lymphomas (24.1%), brain tumors (1%), and other solid tumors (24.7%), compared to 22.3%, 19.3%, 28.6%, and 26.5% in UKK, respectively. Patients from SECI were younger (5.2 vs. 9.0 years, P < 0.001), needed longer travel time to reach the treatment center (1.44 ± 0.07 vs. 0.53 ± 0.03 h, P < 0.001), received therapy earlier (7.53 ± 0.59 vs. 12.09 ± 1.01 days, P = 0.034), showed less compliance (85.1% vs. 97.1%, P < 0.001), and relapsed earlier (7 vs. 12 months, P = 0.008). Deaths in SECI were more frequent (47.4% vs. 18.1%) and caused mainly by infection (60% in SECI, 7% in UKK), while in UKK, they were primarily disease-related (79% in UKK, 27.7% in SECI). Differences in overall and event-free survival were observed for leukemias but not for non-Hodgkin lymphoma. Conclusions: Outcome differences were associated with different causes of death and other less prominent factors.
- 15 February 2023
- Published by S. Karger AG in Digestive Surgery
- Vol. 40 (1-2) , 31-38
Revision of Vertical Banded Gastroplasty to Roux-En-Y Gastric Bypass with 2 Years of Follow-Up
Background: Due to weight regain and GIT symptoms associated with vertical banded gastroplasty (VBG), revisional surgery is necessary. Roux-en-Y gastric bypass (RYGB) is one of the best options as a revision procedure but comes with a high complication rate. Methods: This prospective study included 80 patients undergoing RYGB surgery at Ain Shams University Hospitals after failed VBG surgery, with up to 2 years of follow-up. Results: Eighty patients underwent RYGB correction after VBG. The mean age was 42 ± 6.45 (39–58) years and the mean preoperative body mass index was 45.46 ± 4.135 (38–55) kg/m2. The median length of hospital stay for the patients was 4.78 ± 1.84 days. The early postoperative complication rate was 8.7% and the reoperation rate within 30 days was 3.75%, with no mortality. Leakage and bowel injury were detected in 2 patients. After an average follow-up of 2 years, the percentage of EWL was 64.47 ± 19.3, and complete resolution of VBG-related GIT symptoms was achieved in approximately all patients. Late complications occurred in 7.5% of patients, of whom 3.75% required surgery. Conclusion: Conversion to RYGB is feasible with a limited short-term complication and reoperation rate; long-term results show a nearly complete resolution of VBG-related symptoms and a statistically significant positive impact on weight loss.
- 15 February 2023
- Published by S. Karger AG in Digestive Surgery
- Vol. 40 (1-2) , 31-38
Revision of Vertical Banded Gastroplasty to Roux-En-Y Gastric Bypass with 2 Years of Follow-Up
Background: Due to weight regain and GIT symptoms associated with vertical banded gastroplasty (VBG), revisional surgery is necessary. Roux-en-Y gastric bypass (RYGB) is one of the best options as a revision procedure but comes with a high complication rate. Methods: This prospective study included 80 patients undergoing RYGB surgery at Ain Shams University Hospitals after failed VBG surgery, with up to 2 years of follow-up. Results: Eighty patients underwent RYGB correction after VBG. The mean age was 42 ± 6.45 (39–58) years and the mean preoperative body mass index was 45.46 ± 4.135 (38–55) kg/m2. The median length of hospital stay for the patients was 4.78 ± 1.84 days. The early postoperative complication rate was 8.7% and the reoperation rate within 30 days was 3.75%, with no mortality. Leakage and bowel injury were detected in 2 patients. After an average follow-up of 2 years, the percentage of EWL was 64.47 ± 19.3, and complete resolution of VBG-related GIT symptoms was achieved in approximately all patients. Late complications occurred in 7.5% of patients, of whom 3.75% required surgery. Conclusion: Conversion to RYGB is feasible with a limited short-term complication and reoperation rate; long-term results show a nearly complete resolution of VBG-related symptoms and a statistically significant positive impact on weight loss.